TY - JOUR T1 - Hematologist-level classification of mature B-cell neoplasm using deep learning on multiparameter flow cytometry data JF - medRxiv DO - 10.1101/2020.03.31.20041442 SP - 2020.03.31.20041442 AU - Max Zhao AU - Nanditha Mallesh AU - Richard Schabath AU - Alexander Höllein AU - Claudia Haferlach AU - Torsten Haferlach AU - Franz Elsner□ AU - Hannes Lüling□ AU - Peter Krawitz AU - Wolfgang Kern Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/04/2020.03.31.20041442.abstract N2 - The wealth of information captured by multiparameter flow cytometry (MFC) can be analyzed by recent methods of computer vision when represented as a single image file. We therefore transformed MFC raw data into a multicolor 2D image by a self-organizing map (SOM) and classified this representation using a convolutional neural network (CNN). By this means, we built an artificial intelligence that is not only able to distinguish diseased from healthy samples, but that can also differentiate seven subtypes of mature B-cell neoplasm (B-NHL). We trained our model with 18,274 cases including chronic lymphocytic leukemia (CLL) and its precursor monoclonal B-cell lymphocytosis (MBL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), prolymphocytic leukemia (PL), follicular lymphoma (FL), hairy cell leukemia (HCL), lymphoplasmacytic lymphoma (LPL) and achieved a weighted F1 score of 0.94 on a separate test set of 2,348 cases. Furthermore, we estimated the trustworthiness of a classification and could classify 70% of all cases with a confidence of 0.95 and higher. Our performance analyses indicate that particularly for rare subtypes further improvement can be expected when even more samples are available for training.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.Z. (primary author) received a PhD grant from Berlin Institute of Health. No additional funding from third parties were received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon reasonable request. Please send request to P.M.K pkrawitz@uni-bonn.de ER -